Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Tepezza (teprotumumab-trbw) is a human monoclonal antibody and insulin-like growth factor-1 receptor (IGF-1R) inhibitor indicated for the treatment of Thyroid Eye Disease (TED), also known as Graves’ orbitopathy. It is the first FDA-approved therapy specifically targeting the underlying pathophysiology of TED. By binding to IGF-1R, Tepezza inhibits the activation of fibroblasts and inflammatory pathways that contribute to orbital tissue expansion and inflammation. This mechanism reduces proptosis, diplopia, and other symptoms associated with active, moderate-to-severe TED.
| Fact Table | |
| Formula | C6408H9848N1692O2004S46 |
| License | US FDA (2020) |
| Bioavailability | Not applicable (IV infusion) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Teprotumumab |
| Elimination half-life | 20 days (approx.) |
| Dosage (Strength) | 10 mg/kg (1st infusion), then 20 mg/kg every 3 weeks for 7 additional infusions (IV) |
| Pregnancy | Contraindicated (may cause fetal harm) |
| Brands | Tepezza |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 135565778 |
| MedlinePlus | a620026 |
| ChEBI | Not available |
| ATC code | L01FX16 |
| DrugBank | DB15108 |
| KEGG | D11922 |
| Routes of administration | Intravenous (IV) |
Tepezza is administered as an intravenous infusion once every three weeks for a total of eight infusions (over approximately 21 weeks). The recommended initial dose is 10 mg/kg followed by 20 mg/kg for each of the remaining seven doses. Infusions should be administered over 90 minutes and patients monitored during and after the infusion for signs of hypersensitivity or infusion-related reactions. Premedication may be considered in patients with a history of infusion reactions.
Tepezza should not be administered to patients with active or untreated inflammatory bowel disease or uncontrolled diabetes without appropriate risk assessment.
Each single-dose vial of Tepezza contains 500 mg of teprotumumab-trbw as a lyophilized powder. Inactive ingredients include L-histidine, L-histidine hydrochloride monohydrate, trehalose dihydrate, and polysorbate 20. After reconstitution and dilution, the solution is administered intravenously.
Tepezza is contraindicated in patients with known hypersensitivity to teprotumumab or any of its excipients. It should not be used in pregnant women due to the potential risk of fetal harm based on its mechanism of action.
Caution is advised in patients with preexisting inflammatory bowel disease (IBD), as exacerbation of IBD has been reported. Patients should be screened for diabetes and blood glucose monitored throughout therapy, as hyperglycemia is a known adverse effect. Female patients of reproductive potential should use effective contraception during treatment and for 6 months after the final dose due to potential embryofetal toxicity. Infusion-related reactions, although uncommon, may require dose interruption or discontinuation.
Common and serious side effects associated with Tepezza include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews